Research bodies and industry should combine efforts to develop biomarkers for dementiaBMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a2258 (Published 24 October 2008) Cite this as: BMJ 2008;337:a2258
- Anne Gulland
A report on mental health has called for medical research bodies and the drug industry to join forces to find biomarkers for the early identification of dementia.
The study, Mental Capital and Wellbeing, says that biomarkers are vital for the prompt detection and monitoring of dementia. Biomarkers are objective biological measures associated with the presence of a disease, increased risk, or response to treatment.
The report, published by Foresight, part of the Government Office for Science, aims to advise the government on how to achieve the best possible mental development and mental wellbeing in …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial